Western drugmakers headed into the BRIC countries to provide the kind of volume growth they couldn't scare up elsewhere. But it is not turning out exactly as planned. India has expanded price controls.
China and India may top the list of fastest-growing pharma markets, but Brazil is no slouch, either. Drugmakers are wheeling and dealing there at an increasingly faster pace, as companies like Merck and Reckitt Benckiser join old-timers like Sanofi and GlaxoSmithKline in beefing up there.
With a clear eye toward expanding its focus on emerging markets, Smith & Nephew this week announced plans to snatch up its long-time Brazilian-based distributor.
Italy is the world's second largest producer of active pharmaceutical ingredients (APIs), trailing only China. It holds nearly a 30% share in the U.S., still the largest market for branded and generic APIs.
Few parts of the world are untouched by some drugmaker as companies of every stripe and size try to tap market growth where they can.
With Western drugmakers sniffing around emerging markets in Latin America and elsewhere for the scent of a good deal, some companies there are weighing their futures, and their values, preparing themselves for the chase.
Valeant Pharmaceuticals CEO Mike Pearson is at it again, whittling down manufacturing capacity Valeant picked up in some of its many acquisitions.
Angel Medical Systems' Guardian System heart monitor is actively being sold in Europe and Brazil. But $27.5 million in new financing will help the company reach the long-awaited regulatory finish line in the U.S.
Emerging markets are now the major driver of growth in the pharmaceutical industry, but multinational pharma companies must tread carefully in order to navigate the local barriers and incentives to market access. Many governments in emerging markets are now making sure pharma companies "pay the toll" for reaping the benefits of their market growth. Read more >>
CareFusion is expanding into Brazil, having inked a deal to buy a device company there focused on ventilators and other respiratory care products. In the grander scheme of things, the acquisition satisfies the company's plans to grow globally, in part, by way of Latin America.